Nkarta (NKTX) EBITDA (2019 - 2026)
Nkarta's quarterly EBITDA came in at -$28.4 million in Q1 2026, up 11.36% year-on-year from -$25.5 million in Q1 2025, and down 3.02% quarter-over-quarter from -$27.5 million in Q4 2025.
Nkarta has reported EBITDA for 8 years, with the latest figure at -$28.4 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA rose 11.36% year-over-year to -$28.4 million; the trailing twelve-month figure through Mar 2026 stood at -$100.7 million (up 8.84% YoY), and the FY2025 full-year result was -$104.4 million, up 3.49% from the prior year.
- EBITDA for Q1 2026 stood at -$28.4 million, down from -$27.5 million in the prior quarter.
- The five-year high for EBITDA was -$21.5 million in Q3 2025, with the low at -$33.7 million in Q2 2023.
- Average EBITDA over 5 years is -$27.8 million, with a median of -$27.3 million recorded in 2023.
- Year-over-year, EBITDA sank 39.27% in 2022 and grew 25.46% in 2024.
- Tracing NKTX's EBITDA over 5 years: stood at -$31.9 million in 2022, then gained by 14.41% to -$27.3 million in 2023, then gained by 1.32% to -$27.0 million in 2024, then retreated by 2.09% to -$27.5 million in 2025, then decreased by 3.02% to -$28.4 million in 2026.
- The last three EBITDA figures came in at -$28.4 million (Q1 2026), -$27.5 million (Q4 2025), and -$21.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | -28.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.37 Mn |
| Dec 31, 2025 | -27.54 Mn |
| Sep 30, 2025 | -21.54 Mn |
| Jun 30, 2025 | -23.27 Mn |
| Mar 31, 2025 | -32.01 Mn |
| Dec 31, 2024 | -26.98 Mn |
| Sep 30, 2024 | -26.37 Mn |
| Jun 30, 2024 | -25.13 Mn |
| Mar 31, 2024 | -29.65 Mn |
| Dec 31, 2023 | -27.34 Mn |
| Sep 30, 2023 | -25.45 Mn |
| Jun 30, 2023 | -33.71 Mn |
| Mar 31, 2023 | -30.31 Mn |
| Dec 31, 2022 | -31.94 Mn |
| Sep 30, 2022 | -28.74 Mn |
| Jun 30, 2022 | -27.25 Mn |
| Mar 31, 2022 | -26.44 Mn |
| Dec 31, 2021 | -22.93 Mn |
| Sep 30, 2021 | -22.39 Mn |
| Jun 30, 2021 | -21.56 Mn |
| Mar 31, 2021 | -19.34 Mn |
| Dec 31, 2020 | -17.90 Mn |
| Sep 30, 2020 | -13.69 Mn |
| Jun 30, 2020 | -51.06 Mn |
| Mar 31, 2020 | -8.71 Mn |
| Dec 31, 2019 | -10.49 Mn |
| Sep 30, 2019 | -2.67 Mn |
| Jun 30, 2019 | -4.84 Mn |